Advocacy | Healthcare


Posted July 24, 2017

CHADD Position Statement on Controlled Substances Measures

CHADD has become aware of state and local policies, including legislation and
regulations, intended to address the misuse of opioids, but which may have unintended
consequences for children and adults prescribed FDA-approved medications to treat attention deficit
hyperactivity disorder (ADHD).

Read the full statement.

Posted May 15, 2017

CHADD’s Position on Patient Access to ADHD Medications

CHADD ascribes to six principles regarding access to medications indicated to treat attention deficit / hyperactivity disorder (ADHD).

Read the full statement. 

Posted May 15, 2017

American Health Care Act

The House of Representatives had been preparing to vote on the American Health Care Act (AHCA), which would repeal significant portions of the Affordable Care Act (ACA or “Obamacare”) and replace them with alternative coverage policies. At this time, the House is not moving forward with a vote on the AHCA.
Read the summary.
Read the full report.
Posted March 24, 2017

Health Insurance Coverage and ADHD

In September 2016, CHADD conducted a survey about health insurance coverage and attention deficit hyperactivity disorder (ADHD) in the United States. More than 1500 people from all 50 states and Washington, D.C. took part in the online survey and answered 15 anonymous questions about their personal experiences seeking access to services and medications for their, or a family member’s ADHD. Read the full preliminary report.
Posted November 15, 2016